CompaniesSirion Therapeutics

Sirion Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (6)
View all

Total Trials

6

As Lead Sponsor

6

As Collaborator

0

Total Enrollment

592

By Phase

PHASE1/PHASE2: 1PHASE2: 5

By Status

COMPLETED: 6
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
NCT04985916
NCT05565950
Hover over trial bars to see details

Recent Trials

NCT05565950Lead Sponsor
AI-09 In Subjects With Glabellar Lines, GL-101
PHASE1/PHASE2Completed
72 participants
Started: Sep 3, 2022 · Completed: Jun 3, 2024
NCT04985916Lead Sponsor
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
PHASE2Completed
280 participants
Started: Jul 19, 2021 · Completed: Feb 8, 2024
NCT03912805Lead Sponsor
ET-01 in Subjects With Lateral Canthal Lines, LCL-209
PHASE2Completed
38 participants
Started: Feb 27, 2019 · Completed: Oct 4, 2019
NCT03839693Lead Sponsor
ET-01 in Subjects With Lateral Canthal Lines, LCL-208
PHASE2Completed
75 participants
Started: Oct 16, 2018 · Completed: Sep 19, 2019
NCT03655691Lead Sponsor
ET-01 in Subjects With Lateral Canthal Lines, LCL-207
PHASE2Completed
79 participants
Started: Aug 16, 2018 · Completed: Apr 11, 2019
View all 6 trials →